Specifically, quantification of CD3+ and CD8+ T-cell densities in two discrete regions of the tumor has been shown to outperform current tumor risk factors, such as differentiation, venous emboli, and lymphatic invasion when predicting patient outcome7. The gene discussed is CD8A; the disease is neoplasm.